UroGen Pharma

URGN

Biotechnology · Healthcare

Exchange

NASDAQ

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Good

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

UroGen Pharma is a specialty pharmaceutical company focused on treating diseases of the urinary tract. Its main product is Jelmyto, a gel-based treatment for a rare type of cancer found in the upper urinary tract, and it also sells Uro-844 (UGN-102) for low-grade bladder cancer. Its customers are urologists and cancer specialists, primarily in the United States.

The company makes money by selling these prescription drugs directly to hospitals and specialty pharmacies. UroGen operates mainly in the US market and is one of the few companies with approved treatments specifically targeting non-muscle-invasive urothelial cancers, giving it a narrow but defensible niche. Its gross margins are very high, around 91%, which is typical for specialty pharma, but the company is still spending heavily on sales and research, resulting in significant operating losses — the key risk is whether it can grow revenue fast enough to reach profitability before needing additional funding.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+199.2% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+73.3% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

11.1%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~10 months

$108M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Revenue accelerating

UroGen Pharma grew revenue 199% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

90.9%

Premium pricing power — 90.9% gross margin

Profit after running costs

Operating Margin

0.2%

Thin — 0.2% operating margin

Return on the money invested

ROCE

0.2%

Weak — 0.2% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+100.3%

Fast-growing sales (+100.3% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-84.3%

Burning cash (-84.3%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial